Posts Tagged ‘Metsera’

From Farsighted to Flailing as the Obesity Market Advances

November 12, 2025 — This is a perilous and exciting time for investing in obesity innovation as the market for treating this disease advances dramatically. On the side of excitement, we note that the David Wainer in the Wall Street Journal predicts that “obesity drugs are about to go mass market.” Perilous for Novo On the side of peril, […]

Ships in Moonlight, painting by Albert Bierstadt

Metsera Spotlights a Monthly Amylin Analog for Obesity

June 10, 2025 — Yesterday, Metsera presented investors with topline data from phase one studies of a new amylin analog for obesity that promises monthly dosing. This is an early stage drug known only by its code name – MET-233i. Metsera is a young biotech company, founded in 2022. The big news here: 8.4% placebo-subtracted weight loss after 36 […]